Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 10 of 53 · 2514 articles
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...
The study describes a specific surgical technique (side-to-end anastomosis) used during ileocecal resection and reports low surgical and endoscopic recurrence over long follow-up, which could be relevant to surgical...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
Cure8 could only read part of this source from ground.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.
Setons are a common surgical tool to manage draining perianal fistulas in Crohn’s disease by keeping tracts open for drainage and reducing infection. A low-cost, catheter-based seton option could be useful in settings...
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib. Open the original article for the full details.
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
People with Crohn's disease often ask whether food additives and artificial sweeteners affect gut microbes or disease activity. This trial directly tests whether sucralose changes the fecal microbiome in adults with...
If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
Parents and clinicians often worry that when solids are started might change a child’s future risk of IBD. This large prospective study found no clear link between timing or patterns of complementary feeding and later...
The article provides up-to-6-year safety data for ontamalimab in people with moderate-to-severe UC and CD, which helps patients and clinicians understand long-term tolerability of this investigational anti–MAdCAM-1...
A trained singer with Crohn's disease showed cyclical vocal changes tied to biologic infusion timing — this could affect quality of life and work for voice-dependent people with IBD.
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...
Simpler patient-reported scores (PRO2/PRO3) were much more often available in routine clinic visits than CDAI or HBI, yet they agreed closely with those indices. That could make regular monitoring and telehealth...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
A multimodal, simpler activity score could improve practical disease monitoring when full ileocolonoscopy isn’t possible and help standardize treat-to-target practice across centers.
Many people with Crohn’s are given dietary limits (here, ~30 g fat/day) after flares or hospitalization. Practical, sustainable food-choice strategies can help patients follow such advice and reduce meal-related stress.
FMT is an active area of research that could affect future IBD treatments; patients with IBD commonly experience obesity and complex care decisions. Updates on FDA-approved FMT products and ongoing Crohn’s studies may...
The review and original research highlighted here focus on AI-driven multi-omics and single-cell approaches that aim to improve biomarker discovery, diagnosis, and personalized treatment strategies relevant to Crohn’s...
Routinely collected healthcare data can reveal how Crohn’s disease is managed and experienced in everyday practice, helping fill gaps left by clinical trials. A broader, data-driven measure of disease burden could better...
A validated prediction score that reliably rules out clinically significant CT findings could reduce unnecessary CT imaging, radiation exposure, and costs for people with Crohn's disease experiencing acute symptoms.
This press release signals a step toward a new local, regenerative approach for treating complex perianal fistulas—a difficult Crohn’s complication with limited options. If clinical trials proceed, the therapy could add...
The study shows functional differences in how Crohn’s versus healthy fecal microbiota ferment substrates, with CD cultures making less beneficial butyrate and more ethanol/amino acids. That could inform future...
This trial tests a non‑invasive capsule that samples the small intestine directly to search for microbial or metabolite signatures linked to symptoms and disease. If successful, it could help researchers identify...
Understanding why some IBD ulcers fail to heal could help researchers develop better treatments or biomarkers to predict healing, which matters because mucosal healing reduces hospitalizations, surgeries, and cancer...
This registry will gather real-world safety and effectiveness data on infliximab in Chinese children with moderate-to-severe Crohn's disease, which can help clinicians and families understand how the drug performs...
IBD and obstructive sleep apnea may influence each other through shared biological processes (barrier dysfunction, dysbiosis, immune activation, intermittent hypoxia), so understanding this could affect screening and...
Viruses in the gut (including bacteriophages) could influence inflammation and the intestinal barrier in IBD, so understanding the virome may point to new research directions or therapies.
The work suggests specific host genes and cell types that might mediate links between gut microbes and IBD, which could direct future laboratory research into mechanisms and potential biomarkers.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Radiation...
Quality of life is often substantially affected in IBD; this study identifies active disease, greater severity, prior surgery, and stricturing Crohn's disease as factors linked to lower HRQoL, highlighting areas...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease and Complications. The original article is from Inflammatory bowel diseases.
Children with Crohn's and their clinicians often need noninvasive, accessible ways to monitor small-bowel disease. If validated elsewhere, IUS with the reported BWT thresholds could reduce reliance on MRE, which is...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Intestinal ultrasound. The original article is from Indian journal of...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Intestinal ultrasound. The original article is from idp.springer.com.
Phase angle, an easy-to-measure BIA parameter, was lower in IBD patients with malnutrition and higher disease activity. Detecting malnutrition earlier could matter for patients' strength, healing, and overall outcomes.
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the full...
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease, Crohn's disease, and Pediatrics and family. The original article is from msn.com.
Cure8 found this source from 8newsnow.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the full...
Children with IBD and their caregivers may be interested in subcutaneous infliximab as an alternative to regular IV infusions because this review suggests it can maintain drug levels and remission after switching, with...
This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from idp.nature.com.
The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.
